KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得

Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.

Michael E Thase, Willie R Earley, Susan G Kozauer, Changzheng Chen, Hassan Lakkis, Suresh Durgam

Neuropsychiatr Dis Treat 22 594893

PMID42344568
PMCIDPMC13289650
DOI10.2147/NDT.S594893
发表日期2026-06-25
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。
摘要

摘要

PURPOSE: Lumateperone is a mechanistically novel Food and Drug Administration-approved antipsychotic to treat schizophrenia, depressive episodes associated with bipolar I and II disorder, and major depressive disorder (MDD). This analysis of the Phase 3, randomized, double-blind, placebo-controlled, multicenter Study 501 (NCT04985942) evaluated the broad efficacy of lumateperone across depression symptoms assessed by Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor and single-item scores. PATIENTS AND METHODS: Eligible adults (18-65 years) met DSM-5 criteria for MDD with inadequate response to 1 or 2 ADTs in the current depressive episode and had MADRS Total score ≥24, Clinical Global Impression-Severity score ≥4, and Quick Inventory of Depressive Symptomatology-Self-Report 16-item score ≥14. Patients were randomized to oral placebo or lumateperone 42 mg adjunctive to ADT for 6 weeks. A post hoc analysis assessed anhedonia symptoms according to MADRS anhedonia factor. MADRS Total score and MADRS anhedonia factor score were analyzed by baseline anhedonia factor score (median value: ≥18). A prospective analysis investigated change in individual MADRS items. RESULTS: Lumateperone+ADT significantly improved anhedonia symptoms versus placebo+ADT at every visit according to MADRS anhedonia factor score (Day 43: least squares mean difference vs adjunctive placebo [LSMD], -2.5; effect size [ES], -0.50; P<0.0001). In patients with baseline anhedonia scores equal to or more than the median, significant improvements in MADRS Total score (LSMD, -5.4; 95% CI, -7.21, -3.59; ES, -0.67; P<0.0001) and anhedonia factor score (LSMD, -2.8; 95% CI, -3.91, -1.65; ES, -0.55; P<0.0001) were observed for lumateperone+ADT versus placebo+ADT at Day 43, with significant between-group differences observed at all study visits. At Day 43, 9 of the 10 MADRS items significantly improved with adjunctive lumateperone compared with adjunctive placebo. CONCLUSION: Lumateperone 42mg+ADT significantly improved symptoms of anhedonia and a broad range of depression symptoms compared with placebo+ADT in patients with MDD with inadequate response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 LS mean change from baseline in MADRS anhedonia factor score a (mITT population). ** P <0.01 ****P <0.0001. LSMD vs placebo. MMRM in the mITT population. For lumateperone + ADT and placebo + ADT, Day 8: n=238 and n=238; Day 15: n=231 and n=239; Day 22: n=227 and n=234; Day 29: n=222 and n=233; Day 36: n=218 and n=231; Day 43: n=216 and n=229. a Composed of 5 individual MADRS item scores: apparent sadness, reported sadness, concentration difficulties, lassitude, and inability to feel.
非 KM Figure
Figure 2Figure 2 LS mean change from baseline in MADRS Total score in patients with baseline anhedonia ( A ) equal to or more than the median and ( B ) less than the median. a * P <0.05 ** P <0.01 ****P <0.0001. LSMD vs placebo. MMRM in the mITT population. For lumateperone + ADT and placebo + ADT, Panel ( A ) Day 8, n=161 and n=154; Day 15: n=156 and n=157; Day 22, n=155 and n=152; Day 29, n=150 and n=153; Day 36, n=145 and n=151; Day 43, n=145 and n=149. For lumateperone + ADT and placebo + ADT, Panel ( B ) Day 8, n=77 and n=84; Day 15: n=75 and n=82; Day 22, n=72 and n=82; Day 29, n=72 and n=80; Day 36, n=73 and n=80; Day 43, n=71 and n=80. a Defined as baseline MADRS anhedonia factor score ≥18 and <18, respectively (median baseline value in the mITT population).
非 KM Figure
Figure 3Figure 3 LS mean change from baseline in MADRS anhedonia factor score a in patients with baseline anhedonia ( A ) equal to or more than the median and ( B ) less than the median. b * P <0.05 *** P <0.001 **** P <0.0001. LSMD vs placebo. MMRM in the mITT population. For lumateperone + ADT and placebo + ADT, Panel ( A ) Day 8, n=161 and n=154; Day 15: n=156 and n=157; Day 22, n=155 and n=152; Day 29, n=150 and n=153; Day 36, n=145 and n=151; Day 43, n=145 and n=149. For lumateperone + ADT and placebo + ADT, Panel ( B ) Day 8, n=77 and n=84; Day 15: n=75 and n=82; Day 22, n=72 and n=82; Day 29, n=72 and n=80; Day 36, n=73 and n=80; Day 43, n=71 and n=80. a Composed of 5 individual MADRS item scores: apparent sadness, reported sadness, concentration difficulties, lassitude, and inability to feel. b Defined as baseline MADRS anhedonia factor score ≥18 and <18, respectively (median baseline value in the mITT population).
非 KM Figure
Figure 4Figure 4 LS mean change from baseline to Day 43 in MADRS individual items (mITT population). ** P <0.01 *** P <0.001 ****P <0.0001. LSMD vs placebo. MMRM in the mITT population. a Items included in the anhedonia factor score.
非 KM Figure